Mediclinic Middle East has signed a memorandum of understanding with Hub71 to support healthcare technology startups through clinical expertise, industry insights and potential collaboration opportunities.
Announced at the Abu Dhabi Future Health Summit 2026, the partnership will see Mediclinic Middle East join Hub71+ Life Sciences, a specialist ecosystem supporting innovation in biotechnology, medical technology and digital health.
Under the agreement, Mediclinic Middle East will engage with health technology startups to provide clinical guidance and help them explore potential applications for their solutions in healthcare settings.
The healthcare provider will also explore technologies relevant to its clinical priorities, including cancer care, fertility and in vitro fertilisation (IVF), musculoskeletal services, chronic disease management, women’s health, virtual care and care delivered beyond hospitals.
The partnership will also include mentorship and knowledge-sharing activities, giving startups opportunities to draw on Mediclinic Middle East’s clinical and operational expertise.
Launched in 2025, Hub71+ Life Sciences supports startups working across biotechnology, medical technology and digital health. Its founding partners include the Department of Health – Abu Dhabi, the Emirates Drug Establishment and the Health, Endurance, Longevity and Medicine (HELM) cluster.
The ecosystem connects startups with healthcare providers, regulators and investors to support the development, validation and commercialisation of healthcare technologies.
Mediclinic Middle East’s participation expands Hub71+ Life Sciences’ network of healthcare partners, providing startups with further opportunities to access clinical expertise and explore collaboration with a healthcare provider.
Author
Discover more from HealthTechAsia
Subscribe to get the latest posts sent to your email.
HealthTechAsia